EASL 2023

EASL 2023
June 21-24, 2023
Vienna, Austria

European Association for the Study of the Liver (EASL) Congress 2023.

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (9)

    Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    • Author(s): Gordon, S
    • epclusa
    • Liver Diseases
    • Poster

    Long term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 phase 3 studies

    • Author(s): Young-Suk Lim
    • vemlidy
    • Liver Diseases
    • Poster

    Transcriptional analysis of HBV infected liver after treatment with selgantolimod reveals longitudinal changes in both inflammation-related pathways and B cell receptor repertoire

    • Author(s): Kolhatkar, N
    • selgantolimod
    • Liver Diseases
    • Poster

    Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study

    • Author(s): Wedemeyer, H
    • bulevirtide
    • Liver Diseases
    • Oral

    Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies

    • Author(s): Buti, M
    • vemlidy
    • Liver Diseases
    • Oral

    Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical trials and Real-World Data

    • Author(s): Esteban, R
    • epclusa
    • Liver Diseases
    • Poster

    Results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis B abstract

    • Author(s): Agarwal, K
    • selgantolimod
    • Liver Diseases
    • Poster

    Continued Treatment of Initial Non & Partial Virologic Responders with Bulevirtide Monotherapy Through Week 96 Leads to Improvement in Virologic & Biochemical Response

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases
    • Poster

    A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of cilofexor in non-cirrhotic subjects with primary sclerosing cholangitis (PRIMIS)

    • Author(s): Trauner M
    • cilofexor
    • Liver Diseases
    • Oral